세계 실험 동물 모델, 3D배양, 오가노이드 시장 규모는 2024년 28억 달러에서 예측기간 동안 CAGR 12.5%로 추이하고 2029년 50억 달러에 달할 것으로 예측되고 있습니다.
동물 모델 부문은 2024년 18억 달러에서 예측 기간 동안 CAGR 12.2%로 추이하고, 2029년에는 32억 달러에 달할 것으로 예측되고 있습니다. 3D 세포 배양 부문은 2024년 10억 달러에서 CAGR 13.2%로 성장을 지속하여 2029년에는 19억 달러에 이를 것으로 예측됩니다.
이 보고서는 세계 실험 동물 모델, 3D 배양, 유기농 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법 규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추이 및 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- Porter's Five Forces 분석
제3장 시장 역학
- 개요
- 시장 성장 촉진요인
- 동물실험의 윤리적 대체법에 주목
- 종양 모델링과 바이오뱅킹 수요 증가
- 오가노이드 기술의 폭넓은 용도에의 채용 확대
- 시장 성장 억제요인
- 세포 배양과 줄기세포의 연구개발을 규제하는 엄격한 정부규제
- 오가노이드를 기존의 조사 방법에 통합할 때의 과제
- 시장 기회
- 의약품 개발, 맞춤형 의료, 이식에의 응용
제4장 규제 상황
제5장 신기술
- 개요
- 3D 프린팅
- 마이크로플루이딕스
- AI와 자동화
- 특허 분석
제6장 시장 세분화 분석
- 세분화의 내역
- 세계의 실험 동물 모델·3D 배양·오가노이드 시장 :동물 모델별
- 동물 모델
- 세계 시장 규모와 예측
- 마우스
- 쥐
- 토끼
- 햄스터
- 기니피그
- 기타
- 세계의 실험 동물 모델·3D 배양·오가노이드 시장 :3D 배양별
- 3D 배양
- 세계 시장 규모와 예측
- 장기 온칩
- 오가노이드
- 장
- 간
- 위
- 췌장
- 폐
- 신장
- 기타
- 스페로이드
- 세계의 실험 동물 모델·3D 배양·오가노이드 시장 :용도별
- 발생 생물학
- 창약과 맞춤형 의료
- 재생 의료
- 감염증의 병리학
- 약물의 독성과 효능의 시험
- 기타
- 지리적 내역
- 세계의 실험 동물 모델·3D 배양·오가노이드 시장 :지역별
- 세계 시장 규모와 예측
- 북미
- 미국
- 캐나다
- 시장 규모와 예측
- 유럽
- 독일
- 영국
- 시장 규모와 예측
- 아시아태평양
- 기타 지역
제7장 경쟁 정보
제8장 실험 동물 모델·3D 배양·오가노이드에 있어서의 지속가능성:ESG의 관점
- ESG: 소개
- 시장에서의 지속가능성
- ESG의 관점
- 환경에 미치는 영향
- 사회적 영향
- 거버넌스
제9장 부록
- 조사 방법
- 약어
- 출처
- 기업 프로파일
- 3D BIOTEK LLC.
- BIO-TECHNE
- CELLINK
- CHARLES RIVER LABORATORIES
- CHERRY BIOTECH
- CORNING INC.
- EMULATE
- GENOWAY
- GREINER BIO-ONE INTERNATIONAL GMBH
- INSPHERO
- MATTEK
- MIMETAS BV
- PEPGEL LLC.
- POIETIS
- TACONIC BIOSCIENCES INC.
- THEWELL BIOSCIENCE INC.
- THERMO FISHER SCIENTIFIC INC.
JHS
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
The animal model market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $1.8 billion in 2024 to reach $3.2 billion by 2029, at a CAGR of 12.2% from 2024 through 2029.
The 3D cell culture market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $1.0 billion in 2024 to reach $1.9 billion by 2029, at a CAGR of 13.2% from 2024 through 2029.
Report Scope
The global laboratory animal models, 3D cultures, and organoids market is identified and explored in this report, as are all significant global companies active in the market. Markets are broken out globally and by geographic region. Additionally, all major animal models and applications are covered in detail. The current report will provide detailed exposure about this market.
This report analyzes market trends using data from 2023, estimates from 2024, projections of compound annual growth rates through 2029 (forecast period 2024-2029), and regional markets. This report will highlight current and future market potential and give a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints, and opportunities. The report also covers market projections for 2029 and the market shares of key players.
This report details market shares for the different segments, their types and applications, end users, and geography. Based on animal models, the market is segmented into gelatin and vegetarian capsules. The market is segmented based on its nutritional, pharmaceutical, and cosmeceutical applications. Based on end users, the market is segmented into pharmaceutical and nutraceutical companies, contract manufacturing companies, and others.
The market has been segmented into significant geographies: North America, Europe, Asia-Pacific, and other world regions. The regional segment includes a detailed analysis of major countries such as the U.S., Germany, the U.K., France, Japan, China, and India.
The report's goals include:
- Analyzing product types and applications.
- Analyzing global market size and segmentation.
- Understanding market constraints and drivers.
- Providing detailed market forecasts up to 2029.
- Assessing market shares, competitiveness, and industry structure.
- Identifying potential long-term impacts on the market.
Report Includes
- 45 data tables and 52 additional tables
- An up-to-date review and analysis of the global markets for the laboratory animal models, 3D cell cultures, and organoids within the industry
- Analysis of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Estimation of the actual market size and market forecast for organoids, and their corresponding market share analysis by product type, application, and geographic region
- Coverage of the current state of the industry structure, novel technological updates and issues surrounding integration of organoids and stringent regulatory constraints, ongoing research activities, and COVID-19 impact on the overall market
- Information on the current trends that significantly affect the basic research, biomedical and other industries where animals are used for toxicity testing and for evaluating the safety and metabolism of chemical compounds
- Analysis of market opportunities with a holistic review of advantages and disadvantages of the 3D cell cultures, animal models, and organoids in the prevailing biopharmaceuticals industry
- Review of selected patents and patent applications on organoids, and emerging developments in the global market
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Assessment of mergers and acquisitions, joint ventures, partnerships, and other market strategies
- A discussion of ESG challenges and practices in the industry
- Company profiles of major players within the industry, including Thermo Fisher Scientific Inc., Corning Inc., genOway, Charles River Laboratories, and Bio-Techne.
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Threat of Substitutes
- Competitiveness in the Industry
Chapter 3 Market Dynamics
- Overview
- Market Drivers
- Growing Focus on Ethical Alternatives to Animal Testing
- Increasing Demand for Tumor Modeling and Biobanking Fuel Market Expansion
- Increasing Adoption of Organoid Technology for Wider Applications
- Market Restraints
- Strict Government Regulations Governing Cell Cultures and Stem Cells R&D
- Challenges in Incorporating Organoids into Existing Research Practices
- Market Opportunities
- Applications in Drug Development, Personalized Medicine, and Transplantation
Chapter 4 Regulatory Landscape
- Regulatory Scenarios
- United States
- EU
- U.K.
- Germany
- India
Chapter 5 Emerging Technologies
- Overview
- 3D Printing
- Microfluidics
- Artificial Intelligence and Automation
- Patent Analysis
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Laboratory Animal Models, 3D Cultures and Organoids, by Animal Model
- Animal Models
- Global Market Size and Forecast
- Mice
- Rats
- Rabbits
- Hamsters
- Guinea Pigs
- Others
- Global Market for Laboratory Animal Models, 3D Cultures and Organoid, by 3D Cultures
- 3D Cultures
- Global Market Size and Forecast
- Organ-on-chip
- Organoids
- Intestine
- Liver
- Stomach
- Pancreas
- Lung
- Kidney
- Others
- Spheroids
- Global Market for Laboratory Animal Models, 3D Cultures and Organoids by Application
- Developmental Biology
- Drug Discovery and Personalized Medicine
- Regenerative Medicine
- Pathology of Infectious Disease
- Drug Toxicity and Efficacy Testing
- Others
- Geographic Breakdown
- Global Market for Laboratory Animal Models, 3D Cultures and Organoids by Region
- Global Market Size and Forecast
- North America
- U.S.
- Canada
- Market Size and Forecast
- Europe
- Germany
- U.K.
- Market Size and Forecast
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Competitive Landscape
- Strategic Analysis
Chapter 8 Sustainability in Laboratory Animal Models, 3D Cultures, and Organoids: An ESG Perspective
- Introduction to ESG
- Sustainability in the Market
- ESG Perspective
- Environmental Impact
- Social Impact
- Governance
Chapter 9 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- 3D BIOTEK LLC.
- BIO-TECHNE
- CELLINK
- CHARLES RIVER LABORATORIES
- CHERRY BIOTECH
- CORNING INC.
- EMULATE
- GENOWAY
- GREINER BIO-ONE INTERNATIONAL GMBH
- INSPHERO
- MATTEK
- MIMETAS B.V.
- PEPGEL LLC.
- POIETIS
- TACONIC BIOSCIENCES INC.
- THEWELL BIOSCIENCE INC.
- THERMO FISHER SCIENTIFIC INC.
